Clene Inc. (CLNN)
NASDAQ: CLNN · IEX Real-Time Price · USD
0.331
-0.026 (-7.28%)
At close: Jul 2, 2024, 4:00 PM
0.338
+0.007 (2.15%)
After-hours: Jul 2, 2024, 7:55 PM EDT
Clene Revenue
Clene had revenue of $620.00K in the twelve months ending March 31, 2024, with 12.73% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $73.00K, a -31.78% decrease year-over-year. In the year 2023, Clene had annual revenue of $654.00K with 38.27% growth.
Revenue (ttm)
$620.00K
Revenue Growth
+12.73%
P/S Ratio
68.57
Revenue / Employee
$7,561
Employees
82
Market Cap
42.51M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 654.00K | 181.00K | 38.27% |
Dec 31, 2022 | 473.00K | -250.00K | -34.58% |
Dec 31, 2021 | 723.00K | 517.00K | 250.97% |
Dec 31, 2020 | 206.00K | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
NeueHealth | 1.11B |
Apyx Medical | 50.45M |
Bionano Genomics | 37.47M |
Daxor | 34.67M |
LAVA Therapeutics | 13.63M |
Lipocine | 4.71M |
Envoy Medical | 297.00K |
CLNN News
- 8 days ago - Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference - GlobeNewsWire
- 11 days ago - Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome - GlobeNewsWire
- 14 days ago - Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting - GlobeNewsWire
- 5 weeks ago - Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP) - GlobeNewsWire
- 7 weeks ago - Clene to Present at Upcoming May Conferences - GlobeNewsWire
- 7 weeks ago - Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights - GlobeNewsWire
- 2 months ago - Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting - GlobeNewsWire
- 3 months ago - Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8® - GlobeNewsWire